Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509047-26-00

Acronym

20220028

Enrollment

135

Registered

2024-05-16

Start date

2024-06-13

Completion date

Unknown

Last updated

2025-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and NSCLC., colorectal cancer (CRC), Dose Escalation: Non-small cell lung cancer (NSCLC), gastric cancer (GC), GC, melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France, Netherlands, Poland, Spain

Outcome results